Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PADI1 | Q9ULC6 | 2/20 | 0.36 |
| ▸ | PADI3 | Q9ULW8 | 2/20 | 0.36 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.36 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2615860 | 0.93 | PADI1 (0.40) | MLYCDTGM2CA1CA2PADI1 | |
| SCHEMBL2099054 | 0.82 | FOLH1 (0.55) | MLYCDFOLH1 | |
| SCHEMBL2628415 | 0.82 | PPARG (0.39) | — | |
| SCHEMBL2101102 | 0.82 | PPARG (0.39) | — | |
| SCHEMBL2631415 | 0.77 | HDAC3 (0.42) | PTPN1 | |
| SCHEMBL12384334 | 0.77 | HDAC3 (0.42) | PTPN1 | |
| SCHEMBL4209003 | 0.76 | CTSK (0.35) | FOLH1 | |
| SCHEMBL13408044 | 0.75 | HDAC6 (0.50) | DRD2DRD3NAMPT | |
| SCHEMBL18044129 | 0.75 | PDF (0.37) | MLYCDCA1CA2 | |
| SCHEMBL2615859 | 0.74 | FOLH1 (0.49) | FOLH1PADI1PADI3PADI4PADI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440988-B2 | Regulators of the hedgehog pathway, compositions and uses related thereto | JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2016-09-13 | — | — | US | disclosed |
| US-20120135066-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | BEACHY PHILIP A (US) | 2012-05-31 | — | — | US | disclosed |
| US-8163719-B2 | Regulators of the hedgehog pathway, compositions and uses related thereto | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110263519-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2011-10-27 | — | — | US | disclosed |
| US-7998946-B2 | Veratrum-type alkaloid inhibits mitotic cell proliferation in hedgehog-mediated signal transduction with an ED50 of 1 mM or less; preparations administered systemically, locally, topically; cancer; non-malignant hyperproliferative disorders | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2011-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135066-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | SHH, GLI1, SMO | MLYCD 1531/4885TGM2 1490/4885FOLH1 840/4885 |
| US-20110263519-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | SHH, GLI1, SMO | MLYCD 1531/4885TGM2 1490/4885FOLH1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.